이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Korea approves emergency use of updated Novavax Covid-19 vaccine

Collected: 2023.11.30

Distributed: 2023.12.01

Source: Go Direct

이미지 확대

[Photo by Reuters / Yonhap]

An updated Covid-19 vaccine developed by the U.S. biotechnology firm Novavax Inc. that has been approved in the United States and Europe will be available in South Korea following an authorization from the Ministry of Food and Drug Safety.

The ministry said on Wednesday that it decided to authorize the emergency use of Novavax’s updated Covid-19 vaccine Nuvaxovid XBB 1.5, a vaccine against XBB.1.5 variants of the SARS-CoV-2 virus.

The recombinant vaccine is indicated for vaccination against Covid-19 by making the immune system identify the protein in the vaccine as foreign and produce natural defenses, such as antibodies, against it.

The recent authorization was due to a request from the Korea Disease Control and Prevention Agency as part of the nation’s vaccination schedule for the winters of 2023 and 2024.

The Nuvaxovid XBB.1.5 has been approved for use by the European Medicines Agency (EMA), while the U.S. Food and Drug Administration (FDA) authorized the vaccine for emergency use.

By Kim Ji-hee and Han Yubin

List

Previous: Hyundai Electric to build power distribution equipment plant in Cheongju

Next: LS MnM invests $900 mn in Saemangeum battery material plant